{"meshTags":["Cyclooxygenase 2 Inhibitors","Disease Progression","Drug Delivery Systems","Farnesyltranstransferase","Gene Targeting","Humans","Metalloproteases","NF-kappa B","Pancreatic Neoplasms","Protease Inhibitors","Receptor, Epidermal Growth Factor","Vascular Endothelial Growth Factor A"],"meshMinor":["Cyclooxygenase 2 Inhibitors","Disease Progression","Drug Delivery Systems","Farnesyltranstransferase","Gene Targeting","Humans","Metalloproteases","NF-kappa B","Pancreatic Neoplasms","Protease Inhibitors","Receptor, Epidermal Growth Factor","Vascular Endothelial Growth Factor A"],"genes":["EGFR","EGFR-tyrosine kinase","VEGF, farnesyl transferase inhibitors, matrix metalloproteinase","COX 2"],"publicationTypes":["Evaluation Studies","Journal Article","Review"],"abstract":"The recent elucidation both of the mechanisms involved in pancreatic cancer carcinogenesis and the related molecular events, has led to several distinct therapeutic advances, including many novel target agents, such as monoclonal antibodies against EGFR, EGFR-tyrosine kinase inhibitors, monoclonal antibody against VEGF, farnesyl transferase inhibitors, matrix metalloproteinase inhibitors, COX 2 inhibitors, and the development of gene therapy to target pancreatic cancer. This review highlights recent findings in the treatment of pancreatic cancer by using these novel therapeutic approaches.","title":"New target therapies in advanced pancreatic cancer.","pubmedId":"16807445"}